ArticleInternational journal of colorectal disease2011
Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy.
Article in International journal of colorectal disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 41 citations in OpenAlex.
- Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer.Molecular oncology · 2016Trial
- Targeting the "undruggable" RAS with biologics.Advances in cancer research · 2022Review
- Selective and noncovalent targeting of RAS mutants for inhibition and degradation.Nature communications · 2021Article
- Article
- KRAS mutation status concordance between the primary tumor and the corresponding metastasis in patients with rectal cancer.PloS one · 2020Article
- Precision cell-free DNA extraction for liquid biopsy by integrated microfluidics.NPJ precision oncology · 2020Article
- RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.Molecular oncology · 2019Article
- Droplet digital PCR revealed high concordance between primary tumors and lymph node metastases in multiplex screening of KRAS mutations in colorectal cancer.Clinical and experimental medicine · 2019Article
- Simple and Low-Cost Sampling of Cell-Free Nucleic Acids from Blood Plasma for Rapid and Sensitive Detection of Circulating Tumor DNA.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2018Article
- Optimal detection of clinically relevant mutations in colorectal carcinoma: sample pooling overcomes intra-tumoral heterogeneity.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients.Oncotarget · 2017Article
- [Association of RAS mutations in circulating cell-free DNA in the plasma with clinicopathological features of colorectal cancer].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2017Article
- Article
- Pragmatic issues in biomarker evaluation for targeted therapies in cancer.Nature reviews. Clinical oncology · 2015Review
- Changes of KRAS Exon 2 Codon 12/13 Mutation Status in Recurrent Colorectal Cancer.Pathology oncology research : POR · 2015Article
- Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.Nature medicine · 2014Article
- The role of personalized medicine in metastatic colorectal cancer: an evolving landscape.Therapeutic advances in gastroenterology · 2013Article
- Targeted therapies in colorectal cancer-an integrative view by PPPM.The EPMA journal · 2013Article
- How many diseases are colorectal cancer?Gastroenterology research and practice · 2012Article
- Genetic and epigenetic traits as biomarkers in colorectal cancer.International journal of molecular sciences · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeK-ras mutations predict resistance against epidermal growth factor receptor (EGFR)-directed therapy of metastatic colorectal cancer (CRC). The purpose of this study was to analyze the distribution of K-ras mutations in primary tumors and corresponding sentinel lymph nodes (SLNs) from colon cancer patients.
methodsTumor biopsies and SLNs from 158 patients with non-metastatic colon cancer were analyzed for K-ras mutations in codons 12 and 13 by a sensitive and quantitative peptide nucleic acid clamp PCR assay.
resultsAnalyses of single fresh-frozen tumor biopsies revealed K-ras mutations in 67 (42%) of the patients. Apparently low levels of K-ras mutations in 13 of the mutated primary tumors and the presence of K-ras mutations in SLNs from seven patients with a wild-type primary tumor biopsy suggested possible intratumoral heterogeneity for 20 of the patients. To confirm this hypothesis, we analyzed tissue sections from all available formalin-fixed, paraffin-embedded (FFPE) tumor blocks from these 20 patients. Ten of the patients had a mixture of tissue sections positive and tissue sections negative for K-ras mutations, two patients had K-ras mutations in all sections, and eight patients had no detectable K-ras mutations in tumor FFPE tissue blocks. Among these eight patients, five had K-ras mutations detected in SLNs. Thus, evidence supporting a heterogeneous distribution of K-ras mutations was obtained for 15 patients.
conclusionsHeterogeneous distribution of K-ras codon 12 and 13 mutations within primary tumor, or between primary tumor and lymph node metastases, was demonstrated for 15 (20%) of 74 colon cancer patients having K-ras mutations. This may have implications for tissue sampling routines with regard to EGFR-directed therapy of CRC, both in adjuvant and metastatic settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.